Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
394
NCT02446340
Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2013
Completion: Apr 30, 2014
NCT02435342
A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis
Start: Oct 31, 2014
Completion: Mar 31, 2015
NCT03993704
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
Start: Sep 16, 2019
Completion: Jun 9, 2020
NCT05708950
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Phase: Phase 1/2
Start: Mar 3, 2023
Completion: Dec 31, 2024